A carregar...

TGF-β2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory Properties

Allogeneic mesenchymal stem cells (MSCs) are a promising cell therapy for treating numerous diseases, but major histocompatibility complex (MHC)-mismatched MSCs can be rejected by the recipient’s immune system. Pre-treating MSCs with transforming growth factor-β2 (TGF-β2) to downregulate surface exp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Cell Dev Biol
Main Authors: Berglund, Alix K., Long, Julie M., Robertson, James B., Schnabel, Lauren V.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7889809/
https://ncbi.nlm.nih.gov/pubmed/33614658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2021.628382
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!